Antiretroviral therapy has led to a significant decrease in human immunodeficiency virus
(HIV)-related mortality. Approved antiretroviral drugs target different steps of the viral life …

Fusion of viral and cellular membranes is an essential step for HIV-1 infection. This process
offers an attractive target for developing antiviral agents. T20 (Enfuvirtide, Fuzeon), a 36 …

Albuvirtide (ABT) is a 3-maleimimidopropionic acid (MPA)-modified peptide HIV fusion
inhibitor that can irreversibly conjugate to serum albumin. Previous studies demonstrated its …

Sifuvirtide (SFT) is an electrostatically constrained α-helical peptide fusion inhibitor showing
potent anti-HIV activity, good safety, and pharmacokinetic profiles, and it is currently under …

Peptides based on the second heptad repeat (HR2) of viral class I fusion proteins are
effective inhibitors of virus entry. One such fusion inhibitor has been approved for treatment …

Viruses need to deliver their genomic information into the host cell lumen to establish
productive infection. Enveloped viruses accomplish this task by fusing their membrane with …

Human immunodeficiency virus type 1 (HIV-1) fusion inhibitors blocking viral entry by
binding the gp41 heptad repeat 1 (HR1) region offer great promise for antiretroviral therapy …

CP32M is a newly designed peptide fusion inhibitor possessing potent anti-HIV activity,
especially against T20-resistant HIV-1 strains. In this study, we show that CP32M can …

Severe limitations exist in the data describing the association of HIV-1 subtypes with
resistance and treatment outcomes, because most data are the result of retrospective …

Up until 10 years ago, basic and clinical HIV-1 research was mainly performed on HIV-1
subtype B that predominated in resource-rich settings. Over the past decade, HIV-1 care and …